top of page


We have developed a highly efficient virus production system based on a fully continuous tubular bioreactor* for virus propagation and a size-based capture chromatography** step for virus purification.

These two technologies can attain a tenfold efficiency compared to current production systems such as batch stirred tanks or packed-bed chromatography. They can be used for a wide range of of virus particles employed in both gene therapy and vaccine applications such as influenza virus, Vaccinia virus, and many serotypes and recombinant variants of AAV.

Our single-use technologies offer the following advantages:

For Gene Therapy/Vaccine Manufacturers
  • Increase capacity with existing footprint: Our tubular bioreactor increases volumetric output up to 20× without increasing bioreactor size (10 L per month with a 0.5 L stirred tank).


  • Scalability​: Our tubular bioreactor and capture chromatography can be used from lab to manufacturing scale, eliminating the need of changing/revalidating processes at larger scales.


  • One-size-fits-all purification solution: Our capture chromatography uses a single recipe for a wide variety of virus classes and serotypes, thus significantly shortening process development times while simultaneously ensuring high product yields.


  • Simultaneous product manufacturing: Our tubular reactor can be used to produce different viruses using one cell seeding reactor.


  • Shorter time to market: high efficiency across scales and reduced footprint minimize production delays for clinical testing.

For Universities/Research Institutes/Start-ups
  • Speed:​ Faster turnaround time and less delays with product delivery thanks to fully continuous product harvest.

  • Higher product recovery: Our high purification yields of more than 90% mean you get back purified most of the sample you send us.

  • Reduced mutation risk: Our tubular bioreactor ensures higher homogeneity of of virus particles thanks to a unidirectional flow that avoids back-mixing.

Learn more about our research by reading our Publications.

If you are interested in helping us evaluate these technologies,

please send an email to


* WO2017190790A1, Tapia F, et al. Plug flow tubular bioreactor, system containing the same and method for production of virus. (Pending)

** WO2017076553A1, Wolff MW, et al. Method for the separation of virus compositions including depletion and purification thereof. (Pending)

bottom of page